General
Preferred name
SELTOREXANT
Synonyms
JNJ-42847922 ()
MIN-202 ()
Seltorexant (hydrochloride) ()
JNJ-42847922 (hydrochloride) ()
P&D ID
PD050544
CAS
1293281-49-8
1293284-49-7
Tags
available
drug candidate
Drug indication
Major depressive disorder
Drug Status
investigational
Max Phase
Phase 3
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Seltorexant (JNJ-42847922) is an investigational, selective OX2 receptor antagonist (2-SORA) . It is one of the compounds claimed in patent WO2011050198, where it is Example 107 . This compound is being developed jointly by Minerva Neurosciences and Janssen Pharmaceuticals for the treatment of major depression disorder and insomnia.
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
6
ChEMBL Drugs
DrugMAP
Guide to Pharmacology
MedChem Express Bioactive Compound Library
ReFrame library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
17
Molecular Weight
407.19
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
0
Rotatable Bonds
3
Ring Count
5
Aromatic Ring Count
3
cLogP
2.02
TPSA
80.04
Fraction CSP3
0.38
Chiral centers
2.0
Largest ring
6.0
QED
0.66
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Neuroscience
Neuronal Signaling
Target
OX2
Orexin Receptor (OX Receptor)
Source data
